Business Segments Atossa Therapeutics, Inc.
Stocks
ATOS
US04962H7044
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-10-02 EDT
|
5-day change | 1st Jan Change | ||
| 2.340 USD | +3.08% |
|
+23.16% | -73.56% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
EBT: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Net Income | -20.61M | -26.96M | -30.09M | -25.5M | -34.77M | |||||
Operating Income | -20.52M | -27.69M | -31.38M | -27.62M | -37.14M | |||||
D&A | 23K | 8K | 23K | 17K | 16K | |||||
EBT | -20.61M | -26.96M | -30.09M | -25.5M | -34.77M | |||||
CAPEX | -9K | -27K | -14K | -19K | -23K | |||||
Total Assets | 141M | 124M | 96.25M | 76.44M | 47.61M |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Operating Income | -20.52M | -27.69M | -31.38M | -27.62M | -37.14M | |||||
EBT | -20.61M | -26.96M | -30.09M | -25.5M | -34.77M | |||||
Net Income | -20.61M | -26.96M | -30.09M | -25.5M | -34.77M | |||||
CAPEX | -9K | -27K | -14K | -19K | -23K | |||||
D&A | 23K | 8K | 23K | 17K | 16K | |||||
Total Assets | 141M | 124M | 96.25M | 76.44M | 47.61M |
- Stock Market
- Stocks
- ATOS Stock
- Financials Atossa Therapeutics, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
